- Home
- PMVP vs TIL Comparison
PMVP vs TIL Comparison
Compare PMVP & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PMVP | TIL |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.0M | 74.7M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PMVP | TIL |
|---|---|---|
| Price | $1.22 | $11.48 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $5.00 | ★ $100.67 |
| AVG Volume (30 Days) | ★ 293.3K | 58.7K |
| Earning Date | 11-12-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.81 | $10.69 |
| 52 Week High | $1.84 | $42.79 |
Technical Indicators
Market Signals| Indicator | PMVP | TIL |
|---|---|---|
| Relative Strength Index (RSI) | 43.95 | 42.30 |
| Support Level | $1.11 | $10.96 |
| Resistance Level | $1.28 | $11.63 |
| Average True Range (ATR) | 0.07 | 0.55 |
| MACD | 0.00 | 0.27 |
| Stochastic Oscillator | 50.00 | 58.80 |
Price Performance
Historical ComparisonAbout PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.